tradingkey.logo
๎™

Equillium Inc

EQ
1.150USD
+0.070+6.48%
์ข…๊ฐ€ย 12/19, 16:00๏ผˆET๏ผ‰์‹œ์„ธ๋Š” 15๋ถ„ ์ง€์—ฐ๋ฉ๋‹ˆ๋‹ค
69.78M์‹œ๊ฐ€์ด์•ก
์†์‹คP/E TTM
๎™

์ž์„ธํ•œ ๋‚ด์šฉ์€ Equillium Inc ํšŒ์‚ฌ

Equillium, Inc. is a clinical-stage biotechnology company. It is engaged in developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need. The Companyโ€™s pipeline consists of immunomodulatory assets and a product platform targeting immuno-inflammatory pathways. Its EQ302 is a selective bi-specific cytokine inhibitor targeting IL-15 and IL-21. EQ101 is a clinical-stage, selective, tri-specific inhibitor of IL-2, IL-9 and IL-15, which are key disease-driving, clinically validated cytokine targets to address unmet needs across a range of immuno-inflammatory indications. Its multi-cytokine platform generates rationally designed composite peptides that selectively block key cytokines at the shared receptor level, targeting pathogenic cytokine redundancies and synergies. The Itolizumab is a monoclonal antibody that targets the CD6-ALCAM signaling pathway, which plays a central role in the modulation of effector T cells.

Equillium Inc ์ •๋ณด

๎™Œ
์ข…๋ชฉ ์ฝ”๋“œ EQ
ํšŒ์‚ฌ ์ด๋ฆ„Equillium Inc
์ƒ์žฅ์ผOct 12, 2018
CEOSteel (Bruce D)
์ง์› ์ˆ˜35
์œ ํ˜•Ordinary Share
ํšŒ๊ณ„ ์—ฐ๋„ ์ข…๋ฃŒOct 12
์ฃผ์†Œ2223 Avenida de La Playa Ste 105
๋„์‹œLA JOLLA
์ฆ๊ถŒ ๊ฑฐ๋ž˜์†ŒNASDAQ OMX - NASDAQ BASIC
๊ตญ๊ฐ€United States of America
์šฐํŽธ ๋ฒˆํ˜ธ92037-3217
์ „ํ™”18584125302
์›น์‚ฌ์ดํŠธhttps://www.equilliumbio.com/home/default.aspx
์ข…๋ชฉ ์ฝ”๋“œ EQ
์ƒ์žฅ์ผOct 12, 2018
CEOSteel (Bruce D)

Equillium Inc์˜ ํšŒ์‚ฌ ์ž„์›์ง„

๎™Œ
์ด๋ฆ„
์ด๋ฆ„/์ง์œ„
์ง์œ„
์ฃผ์‹ ๋ณด์œ 
๋ณ€๋™
Mr. Bruce D. Steel
Mr. Bruce D. Steel
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
3.71M
--
Dr. Stephen Connelly, Ph.D.
Dr. Stephen Connelly, Ph.D.
President, Chief Scientific Officer
President, Chief Scientific Officer
993.00K
--
Ms. Christine Zedelmayer
Ms. Christine Zedelmayer
Chief Operating Officer
Chief Operating Officer
127.15K
-5.99%
Mr. Charles Douglas Mcdermott
Mr. Charles Douglas Mcdermott
Independent Director
Independent Director
23.80K
--
Dr. Mark Pruzanski, M.D.
Dr. Mark Pruzanski, M.D.
Independent Director
Independent Director
23.80K
--
Ms. Martha J. Demski
Ms. Martha J. Demski
Independent Director
Independent Director
23.80K
--
Dr. Barbara Troupin, M.D.
Dr. Barbara Troupin, M.D.
Independent Director
Independent Director
--
--
Mr. Daniel Mark (Dan) Bradbury
Mr. Daniel Mark (Dan) Bradbury
Executive Chairman of the Board
Executive Chairman of the Board
--
--
Mr. Peter Colabuono
Mr. Peter Colabuono
Director
Director
--
--
์ด๋ฆ„
์ด๋ฆ„/์ง์œ„
์ง์œ„
์ฃผ์‹ ๋ณด์œ 
๋ณ€๋™
Mr. Bruce D. Steel
Mr. Bruce D. Steel
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
3.71M
--
Dr. Stephen Connelly, Ph.D.
Dr. Stephen Connelly, Ph.D.
President, Chief Scientific Officer
President, Chief Scientific Officer
993.00K
--
Ms. Christine Zedelmayer
Ms. Christine Zedelmayer
Chief Operating Officer
Chief Operating Officer
127.15K
-5.99%
Mr. Charles Douglas Mcdermott
Mr. Charles Douglas Mcdermott
Independent Director
Independent Director
23.80K
--
Dr. Mark Pruzanski, M.D.
Dr. Mark Pruzanski, M.D.
Independent Director
Independent Director
23.80K
--
Ms. Martha J. Demski
Ms. Martha J. Demski
Independent Director
Independent Director
23.80K
--

์ˆ˜์ต ๋ถ„์„

๊ธฐ์—…์ด ์•„์ง ๊ด€๋ จ ๋ฐ์ดํ„ฐ๋ฅผ ๊ณต๊ฐœํ•˜์ง€ ์•Š์•˜์Šต๋‹ˆ๋‹ค.
๊ธฐ์—…์ด ์•„์ง ๊ด€๋ จ ๋ฐ์ดํ„ฐ๋ฅผ ๊ณต๊ฐœํ•˜์ง€ ์•Š์•˜์Šต๋‹ˆ๋‹ค.
์‚ฌ์—…๋ณ„
์ง€์—ญ๋ณ„
๊ธฐ์—…์ด ์•„์ง ๊ด€๋ จ ๋ฐ์ดํ„ฐ๋ฅผ ๊ณต๊ฐœํ•˜์ง€ ์•Š์•˜์Šต๋‹ˆ๋‹ค.

์ฃผ์‹ ๋ณด์œ  ํ†ต๊ณ„

๋งˆ์ง€๋ง‰ ์—…๋ฐ์ดํŠธ: Tue, Dec 2
๋งˆ์ง€๋ง‰ ์—…๋ฐ์ดํŠธ: Tue, Dec 2
์ฃผ์ฃผ
์ฃผ์ฃผ ์œ ํ˜•
์ฃผ์ฃผ
์ฃผ์ฃผ
๋น„์œจ
Adar1 Capital Management LLC
9.13%
Adage Capital Management, L.P.
8.75%
Decheng Capital LLC
7.30%
Steel (Bruce D)
6.10%
Bradbury (Daniel M)
6.10%
๊ธฐํƒ€
62.62%
์ฃผ์ฃผ
์ฃผ์ฃผ
๋น„์œจ
Adar1 Capital Management LLC
9.13%
Adage Capital Management, L.P.
8.75%
Decheng Capital LLC
7.30%
Steel (Bruce D)
6.10%
Bradbury (Daniel M)
6.10%
๊ธฐํƒ€
62.62%
์ฃผ์ฃผ ์œ ํ˜•
์ฃผ์ฃผ
๋น„์œจ
Hedge Fund
30.25%
Individual Investor
14.29%
Venture Capital
7.30%
Corporation
6.80%
Investment Advisor
6.58%
Investment Advisor/Hedge Fund
1.69%
Research Firm
0.04%
๊ธฐํƒ€
33.04%

๊ธฐ๊ด€ ์ฃผ์‹ ๋ณด์œ 

๎™Œ
๋งˆ์ง€๋ง‰ ์—…๋ฐ์ดํŠธ: Mon, Dec 8
๋งˆ์ง€๋ง‰ ์—…๋ฐ์ดํŠธ: Mon, Dec 8
๋ณด๊ณ  ๊ธฐ๊ฐ„
๊ธฐ๊ด€ ์ˆ˜
๋ณด์œ  ์ฃผ์‹
๋น„์œจ
๋ณ€๋™
2025Q4
56
7.85M
12.39%
--
2025Q3
59
8.01M
14.05%
+864.85K
2025Q2
59
7.14M
25.07%
+147.35K
2025Q1
58
7.00M
29.82%
-3.62M
2024Q4
64
7.04M
30.80%
-78.37K
2024Q3
65
7.11M
31.78%
-174.81K
2024Q2
62
7.25M
31.46%
+13.34K
2024Q1
61
7.23M
32.13%
-4.10M
2023Q4
55
7.65M
34.25%
-1.47M
2023Q3
57
9.12M
36.17%
-799.05K
๋” ๋ณด๊ธฐ

์ฃผ์ฃผ ํ™œ๋™

๎™Œ
์ด๋ฆ„
๋ณด์œ  ์ฃผ์‹
๋น„์œจ
๋ณ€๋™
Chg %
๋‚ ์งœ
Decheng Capital LLC
4.45M
7.26%
--
--
Jun 30, 2025
Steel (Bruce D)
3.71M
6.06%
--
--
Apr 01, 2025
Bradbury (Daniel M)
3.71M
6.06%
--
--
Apr 01, 2025
Biocon SA
2.32M
3.78%
--
--
Apr 01, 2025
Takeda Pharmaceutical Co Ltd
1.82M
2.98%
--
--
Jun 30, 2025
๋” ๋ณด๊ธฐ

๊ด€๋ จ ETF

๎™Œ
๋งˆ์ง€๋ง‰ ์—…๋ฐ์ดํŠธ: Sat, Dec 6
๋งˆ์ง€๋ง‰ ์—…๋ฐ์ดํŠธ: Sat, Dec 6
์ด๋ฆ„
๋น„์œจ
iShares Micro-Cap ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
0%
Avantis US Small Cap Value ETF
0%
Avantis US Small Cap Equity ETF
0%
iShares Micro-Cap ETF
๋น„์œจ0%
iShares Core S&P Total U.S. Stock Market ETF
๋น„์œจ0%
Avantis US Small Cap Value ETF
๋น„์œจ0%
Avantis US Small Cap Equity ETF
๋น„์œจ0%

์ฃผ์‹ ๋ฐฐ๋‹น๊ธˆ

๎™Œ
์ง€๋‚œ 5๋…„ ๋™์•ˆ ์ด 0.00 USD์˜ ๋ฐฐ๋‹น๊ธˆ์ด ๋ถ„๋ฐฐ๋˜์—ˆ์Šต๋‹ˆ๋‹ค.
๋‚ ์งœ
๋ฐฐ๋‹น๊ธˆ
๊ธฐ์ค€์ผ
์ง€๊ธ‰์ผ
๋ฐฐ๋‹น๋ฝ์ผ
๋ฐ์ดํ„ฐ ์—†์Œ

์ฃผ์‹ ๋ถ„ํ• 

๎™Œ
๋‚ ์งœ
์œ ํ˜•
๋น„์œจ
๋ฐ์ดํ„ฐ ์—†์Œ
๋‚ ์งœ
์œ ํ˜•
๋น„์œจ
๋ฐ์ดํ„ฐ ์—†์Œ

์ž์ฃผ ๋ฌป๋Š” ์งˆ๋ฌธ

Equillium Inc์˜ ์ƒ์œ„ 5๋Œ€ ์ฃผ์ฃผ๋Š” ๋ˆ„๊ตฌ์ธ๊ฐ€์š”?

๎™Œ
Equillium Inc์˜ ์ƒ์œ„ 5๋Œ€ ์ฃผ์ฃผ๋Š” ๋‹ค์Œ๊ณผ ๊ฐ™์Šต๋‹ˆ๋‹ค:
Decheng Capital LLC๋Š” 4.45M์ฃผ์˜ ์ฃผ์‹์„ ๋ณด์œ ํ•˜๊ณ  ์žˆ์œผ๋ฉฐ, ์ „์ฒด ์ฃผ์‹์˜ 7.26%๋ฅผ ์ฐจ์ง€ํ•ฉ๋‹ˆ๋‹ค.
Steel (Bruce D)๋Š” 3.71M์ฃผ์˜ ์ฃผ์‹์„ ๋ณด์œ ํ•˜๊ณ  ์žˆ์œผ๋ฉฐ, ์ „์ฒด ์ฃผ์‹์˜ 6.06%๋ฅผ ์ฐจ์ง€ํ•ฉ๋‹ˆ๋‹ค.
Bradbury (Daniel M)๋Š” 3.71M์ฃผ์˜ ์ฃผ์‹์„ ๋ณด์œ ํ•˜๊ณ  ์žˆ์œผ๋ฉฐ, ์ „์ฒด ์ฃผ์‹์˜ 6.06%๋ฅผ ์ฐจ์ง€ํ•ฉ๋‹ˆ๋‹ค.
Biocon SA๋Š” 2.32M์ฃผ์˜ ์ฃผ์‹์„ ๋ณด์œ ํ•˜๊ณ  ์žˆ์œผ๋ฉฐ, ์ „์ฒด ์ฃผ์‹์˜ 3.78%๋ฅผ ์ฐจ์ง€ํ•ฉ๋‹ˆ๋‹ค.
Takeda Pharmaceutical Co Ltd๋Š” 1.82M์ฃผ์˜ ์ฃผ์‹์„ ๋ณด์œ ํ•˜๊ณ  ์žˆ์œผ๋ฉฐ, ์ „์ฒด ์ฃผ์‹์˜ 2.98%๋ฅผ ์ฐจ์ง€ํ•ฉ๋‹ˆ๋‹ค.

Equillium Inc์˜ ์ƒ์œ„ 3๋Œ€ ์ฃผ์ฃผ ์œ ํ˜•์€ ๋ฌด์—‡์ธ๊ฐ€์š”?

๎™Œ
Equillium Inc์˜ ์ฃผ์š” ์ฃผ์ฃผ ์œ ํ˜• ์ƒ์œ„ 3๊ฐ€์ง€๋Š”
Adar1 Capital Management LLC
Adage Capital Management, L.P.
Decheng Capital LLC์ž…๋‹ˆ๋‹ค.

Equillium Inc(EQ)์˜ ์ฃผ์‹์„ ๋ณด์œ ํ•œ ๊ธฐ๊ด€์€ ๋ช‡ ๊ฐœ์ž…๋‹ˆ๊นŒ?

๎™Œ
2025Q4 ๊ธฐ์ค€์œผ๋กœ, Equillium Inc์˜ ์ฃผ์‹์„ ๋ณด์œ ํ•œ ๊ธฐ๊ด€์€ ์ด 56๊ณณ์ด๋ฉฐ, ์ด๋“ค์ด ๋ณด์œ ํ•œ ์ฃผ์‹์˜ ์ด ๊ฐ€์น˜๋Š” ์•ฝ 7.85M๋กœ ์ „์ฒด ๋ฐœํ–‰ ์ฃผ์‹์˜ 12.39%๋ฅผ ์ฐจ์ง€ํ•ฉ๋‹ˆ๋‹ค. ์ด๋Š” 2025Q3 ๋Œ€๋น„ -1.67% ์ฆ๊ฐ€ํ•œ ์ˆ˜์น˜์ž…๋‹ˆ๋‹ค.

Equillium Inc์˜ ์ตœ๋Œ€ ์ˆ˜์ต์›์€ ๋ฌด์—‡์ธ๊ฐ€์š”?

๎™Œ
-- ๊ธฐ์ค€, Equillium Inc์˜ -- ๋ถ€๋ฌธ์ด ๊ฐ€์žฅ ๋†’์€ ๋งค์ถœ์„ ๊ธฐ๋กํ–ˆ์œผ๋ฉฐ, ๊ธˆ์•ก์€ --๋กœ ์ „์ฒด ๋งค์ถœ์˜ --%๋ฅผ ์ฐจ์ง€ํ–ˆ์Šต๋‹ˆ๋‹ค.
KeyAI
๎™